European Heart Journal Advance Access published online on December 8, 2005
European Heart Journal, doi:10.1093/eurheartj/ehi687
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 University of Alabama at Birmingham, VA Medical Center, 1530 3rd Avenue South, CH-19, Ste-219, Birmingham, AL35294-2041, USA
* To whom correspondence should be addressed. Aims To determine the effects of digoxin on all-cause mortality and heart failure (HF) hospitalizations, regardless of ejection fraction, accounting for serum digoxin concentration (SDC). Methods and results This comprehensive post-hoc analysis of the randomized controlled Digitalis Investigation Group trial (n = 7788) focuses on 5548 patients: 1687 with SDC, drawn randomly at 1 month, and 3861 placebo patients, alive at 1 month. Overall, 33% died and 31% had HF hospitalizations during a 40-month median follow-up. Compared with placebo, SDC 0.5-0.9 ng/mL was associated with lower mortality [29 vs. 33% placebo; adjusted hazard ratio (AHR), 0.77; 95% confidence interval (CI), 0.67-0.89], all-cause hospitalizations (64 vs. 67% placebo; AHR, 0.85; 95% CI, 0.78-0.92) and HF hospitalizations (23 vs. 33% placebo; AHR, 0.62; 95% CI, 0.54-0.72). SDC Conclusions Digoxin at SDC 0.5-0.9 ng/mL reduces mortality and hospitalizations in all HF patients, including those with preserved systolic function. At higher SDC, digoxin reduces HF hospitalization but has no effect on mortality or all-cause hospitalizations.
Received October 17, 2005
Revised November 14, 2005
Accepted November 25, 2005
Clinical research
Digoxin and reduction in mortality and hospitalization inheart failure: a comprehensive post hoc analysis of the DIG trial
Ali Ahmed 1 *,
Michael W. Rich 2,
Thomas E. Love 3,
Donald M. Lloyd-Jones 4,
Inmaculada B. Aban 5,
Wilson S. Colucci 6,
Kirkwood F. Adams 7,
and
Mihai Gheorghiade 4
2 Washington University, St Louis, MO, USA
3 Case Western Reserve University, Cleveland, OH, USA
4 Northwestern University, Chicago, IL, USA
5 University of Alabama at Birmingham, Birmingham, AL, USA
6 Boston University, Boston, MA, USA
7 University of North Carolina, Chapel Hill, NC, USA
Ali Ahmed, E-mail: aahmed{at}uab.edu
![]()
Abstract
1.0 ng/mL was associated with lower HF hospitalizations (29 vs. 33% placebo; AHR, 0.68; 95% CI, 0.59-0.79), without any effect on mortality. SDC 0.5-0.9 reduced mortality in a wide spectrum of HF patients and had no interaction with ejection fraction > 45% (P = 0.834) or sex (P = 0.917).![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. Gheorghiade and E. Braunwald Reconsidering the Role for Digoxin in the Management of Acute Heart Failure Syndromes JAMA, November 18, 2009; 302(19): 2146 - 2147. [Full Text] [PDF] |
||||
![]() |
M. I. Ahmed, M. White, O. J. Ekundayo, T. E. Love, I. Aban, B. Liu, W. S. Aronow, and A. Ahmed A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: a propensity-matched study Eur. Heart J., August 2, 2009; 30(16): 2029 - 2037. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Krishnamoorthy and G. Y.H. Lip How safe is the antiarrhythmic drug therapy in atrial fibrillation? Europace, July 1, 2009; 11(7): 837 - 839. [Full Text] [PDF] |
||||
![]() |
K. Tzanetos, D. Leong, and R. C. Wu Office management of patients with diastolic heart failure Can. Med. Assoc. J., March 3, 2009; 180(5): 520 - 527. [Full Text] [PDF] |
||||
![]() |
J. G.F. Cleland and D. Cullington Digoxin: Quo Vadis? Circ Heart Fail, March 1, 2009; 2(2): 81 - 85. [Full Text] [PDF] |
||||
![]() |
M. Gheorghiade and P. S. Pang Acute heart failure syndromes. J. Am. Coll. Cardiol., February 17, 2009; 53(7): 557 - 573. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Campbell, X. Sui, G. Filippatos, T. E. Love, C. Wahle, P. W. Sanders, and A. Ahmed Association of chronic kidney disease with outcomes in chronic heart failure: a propensity-matched study Nephrol. Dial. Transplant., January 1, 2009; 24(1): 186 - 193. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J.F. Holubarsch, W. S. Colucci, T. Meinertz, W. Gaus, M. Tendera, and Survival and Prognosis: Investigation of Crataegus The efficacy and safety of Crataegus extract WS(R) 1442 in patients with heart failure: The SPICE trial Eur J Heart Fail, December 1, 2008; 10(12): 1255 - 1263. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C. Austin Primer on Statistical Interpretation or Methods Report Card on Propensity-Score Matching in the Cardiology Literature From 2004 to 2006: A Systematic Review Circ Cardiovasc Qual Outcomes, September 1, 2008; 1(1): 62 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ahmed, I. B Aban, V. Vaccarino, D. M Lloyd-Jones, D. C Goff Jr, J. Zhao, T. E Love, C. Ritchie, F. Ovalle, G. Gambassi, et al. A propensity-matched study of the effect of diabetes on the natural history of heart failure: variations by sex and age Heart, December 1, 2007; 93(12): 1584 - 1590. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. von Lewinski, E. Bisping, A. Elgner, J. Kockskamper, and B. Pieske Mechanistic insight into the functional and toxic effects of Strophanthidin in the failing human myocardium Eur J Heart Fail, November 1, 2007; 9(11): 1086 - 1094. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Fenton and M. Burch Understanding chronic heart failure Arch. Dis. Child., September 1, 2007; 92(9): 812 - 816. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Schoner and G. Scheiner-Bobis Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth Am J Physiol Cell Physiol, August 1, 2007; 293(2): C509 - C536. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ahmed, F. Zannad, T. E. Love, J. Tallaj, M. Gheorghiade, O. J. Ekundayo, and B. Pitt A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure Eur. Heart J., June 1, 2007; 28(11): 1334 - 1343. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Metra, P. Ponikowski, K. Dickstein, J. J.V. McMurray, A. Gavazzi, C.-H. Bergh, A. G. Fraser, T. Jaarsma, A. Pitsis, P. Mohacsi, et al. Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail, June 1, 2007; 9(6-7): 684 - 694. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Saposnik and M. K. Kapral Poststroke Care: Chronicles of a Neglected Battle Stroke, June 1, 2007; 38(6): 1727 - 1729. [Full Text] [PDF] |
||||
![]() |
A. Ahmed Digoxin and Reduction in Mortality and Hospitalization in Geriatric Heart Failure: Importance of Low Doses and Low Serum Concentrations J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2007; 62(3): 323 - 329. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ahmed, J. B. Young, and M. Gheorghiade The underuse of digoxin in heart failure, and approaches to appropriate use Can. Med. Assoc. J., February 27, 2007; 176(5): 641 - 643. [Full Text] [PDF] |
||||
![]() |
G. A. Heckman and R. S. McKelvie Necessary cautions when considering digoxin in heart failure Can. Med. Assoc. J., February 27, 2007; 176(5): 644 - 645. [Full Text] [PDF] |
||||
![]() |
J. Elkareh, D. J. Kennedy, B. Yashaswi, S. Vetteth, A. Shidyak, E. G. R. Kim, S. Smaili, S. M. Periyasamy, I. M. Hariri, L. Fedorova, et al. Marinobufagenin Stimulates Fibroblast Collagen Production and Causes Fibrosis in Experimental Uremic Cardiomyopathy Hypertension, January 1, 2007; 49(1): 215 - 224. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G.F. Cleland, M. Tendera, J. Adamus, N. Freemantle, L. Polonski, J. Taylor, and on behalf of PEP-CHF Investigators The perindopril in elderly people with chronic heart failure (PEP-CHF) study Eur. Heart J., October 1, 2006; 27(19): 2338 - 2345. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ahmed, M. W. Rich, J. L. Fleg, M. R. Zile, J. B. Young, D. W. Kitzman, T. E. Love, W. S. Aronow, K. F. Adams Jr, and M. Gheorghiade Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure: The Ancillary Digitalis Investigation Group Trial Circulation, August 1, 2006; 114(5): 397 - 403. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Rahimtoola Digoxin and reduction in mortality in systolic and diastolic heart failure at low serum digoxin concentrations Eur. Heart J., July 1, 2006; 27(13): 1630 - 1630. [Full Text] [PDF] |
||||
![]() |
A. Ahmed, M. W. Rich, I. B. Aban, and M. Gheorghiade Digoxin and reduction in mortality and hospitalization in systolic and diastolic heart failure at low serum digoxin concentrations: reply Eur. Heart J., July 1, 2006; 27(13): 1630 - 1631. [Full Text] [PDF] |
||||
![]() |
A. Ahmed, A. Husain, T. E. Love, G. Gambassi, L. J. Dell'Italia, G. S. Francis, M. Gheorghiade, R. M. Allman, S. Meleth, and R. C. Bourge Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods Eur. Heart J., June 2, 2006; 27(12): 1431 - 1439. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gheorghiade, D. J. van Veldhuisen, and W. S. Colucci Contemporary Use of Digoxin in the Management of Cardiovascular Disorders Circulation, May 30, 2006; 113(21): 2556 - 2564. [Full Text] [PDF] |
||||
![]() |
J. M. Brophy Rehabilitating digoxin Eur. Heart J., January 2, 2006; 27(2): 127 - 129. [Full Text] [PDF] |
||||















